134 related articles for article (PubMed ID: 30102763)
21. Humoral immune response to fibrillar beta-amyloid peptide.
Miller DL; Currie JR; Mehta PD; Potempska A; Hwang YW; Wegiel J
Biochemistry; 2003 Oct; 42(40):11682-92. PubMed ID: 14529278
[TBL] [Abstract][Full Text] [Related]
22. E. coli expression of TIMP-4 and comparative kinetic studies with TIMP-1 and TIMP-2: insights into the interactions of TIMPs and matrix metalloproteinase 2 (gelatinase A).
Troeberg L; Tanaka M; Wait R; Shi YE; Brew K; Nagase H
Biochemistry; 2002 Dec; 41(50):15025-35. PubMed ID: 12475252
[TBL] [Abstract][Full Text] [Related]
23. Quantitative mapping of binding specificity landscapes for homologous targets by using a high-throughput method.
Aharon L; Aharoni SL; Radisky ES; Papo N
Biochem J; 2020 May; 477(9):1701-1719. PubMed ID: 32296833
[TBL] [Abstract][Full Text] [Related]
24. Development of a periplasmic FRET screening method for protease inhibitory antibodies.
Nam DH; Ge X
Biotechnol Bioeng; 2013 Nov; 110(11):2856-64. PubMed ID: 23703626
[TBL] [Abstract][Full Text] [Related]
25. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
26. Targeting a Designer TIMP-1 to the Cell Surface for Effective MT1-MMP Inhibition: A Potential Role for the Prion Protein in Renal Carcinoma Therapy.
Jiang B; Liu J; Lee MH
Molecules; 2019 Jan; 24(2):. PubMed ID: 30641935
[TBL] [Abstract][Full Text] [Related]
27. Yeast display of engineered antibody domains.
Zhao Q; Zhu Z; Dimitrov DS
Methods Mol Biol; 2012; 899():73-84. PubMed ID: 22735947
[TBL] [Abstract][Full Text] [Related]
28. Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B.
Fan Y; Dong J; Lou J; Wen W; Conrad F; Geren IN; Garcia-Rodriguez C; Smith TJ; Smith LA; Ho M; Pires-Alves M; Wilson BA; Marks JD
Toxins (Basel); 2015 Aug; 7(9):3405-23. PubMed ID: 26343720
[TBL] [Abstract][Full Text] [Related]
29. Direct production of functional matrix metalloproteinase--14 without refolding or activation and its application for in vitro inhibition assays.
Nam DH; Ge X
Biotechnol Bioeng; 2016 Apr; 113(4):717-23. PubMed ID: 26416249
[TBL] [Abstract][Full Text] [Related]
30. Lumican: a new inhibitor of matrix metalloproteinase-14 activity.
Pietraszek K; Chatron-Colliet A; Brézillon S; Perreau C; Jakubiak-Augustyn A; Krotkiewski H; Maquart FX; Wegrowski Y
FEBS Lett; 2014 Nov; 588(23):4319-24. PubMed ID: 25304424
[TBL] [Abstract][Full Text] [Related]
31. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
Chen Y; Wiesmann C; Fuh G; Li B; Christinger HW; McKay P; de Vos AM; Lowman HB
J Mol Biol; 1999 Nov; 293(4):865-81. PubMed ID: 10543973
[TBL] [Abstract][Full Text] [Related]
32. Optimizing properties of antireceptor antibodies using kinetic computational models and experiments.
Harms BD; Kearns JD; Su SV; Kohli N; Nielsen UB; Schoeberl B
Methods Enzymol; 2012; 502():67-87. PubMed ID: 22208982
[TBL] [Abstract][Full Text] [Related]
33. Ensnaring membrane type 1-matrix metalloproteinase (MT1-MMP) with tissue inhibitor of metalloproteinase (TIMP)-2 using the haemopexin domain of the protease as a carrier: a targeted approach in cancer inhibition.
Jiang B; Zhang Y; Liu J; Tsigkou A; Rapti M; Lee MH
Oncotarget; 2017 Apr; 8(14):22685-22699. PubMed ID: 28186971
[TBL] [Abstract][Full Text] [Related]
34. Potent and selective inhibition of membrane-type serine protease 1 by human single-chain antibodies.
Sun J; Pons J; Craik CS
Biochemistry; 2003 Feb; 42(4):892-900. PubMed ID: 12549907
[TBL] [Abstract][Full Text] [Related]
35. Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains.
Chen IJ; Chuang CH; Hsieh YC; Lu YC; Lin WW; Huang CC; Cheng TC; Cheng YA; Cheng KW; Wang YT; Chen FM; Cheng TL; Tzou SC
Sci Rep; 2017 Sep; 7(1):11587. PubMed ID: 28912497
[TBL] [Abstract][Full Text] [Related]
36. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
[TBL] [Abstract][Full Text] [Related]
37. Inducible expression of tissue inhibitor of metalloproteinases-resistant matrix metalloproteinase-9 on the cell surface of neutrophils.
Owen CA; Hu Z; Barrick B; Shapiro SD
Am J Respir Cell Mol Biol; 2003 Sep; 29(3 Pt 1):283-94. PubMed ID: 12663332
[TBL] [Abstract][Full Text] [Related]
38. Detection of a latent soluble form of membrane type 1 matrix metalloprotease bound with tissue inhibitor of matrix metalloproteinases-2 in periprosthetic tissues and fluids from loose arthroplasty endoprostheses.
Niarakis A; Giannopoulou E; Ravazoula P; Panagiotopoulos E; Zarkadis IK; Aletras AJ
FEBS J; 2013 Dec; 280(24):6541-55. PubMed ID: 24112707
[TBL] [Abstract][Full Text] [Related]
39. Alanine scanning mutagenesis of SP70 epitope in characterizing species‑specific antibodies induced by enterovirus 71‑based antigens.
Gao M; Zhang F; Zhu Y; Gao L; Jiang Y; Luo Y; Zhuang F; Mao Z; Mao J
Mol Med Rep; 2018 Jan; 17(1):1006-1014. PubMed ID: 29115505
[TBL] [Abstract][Full Text] [Related]
40. Dimerization of endogenous MT1-MMP is a regulatory step in the activation of the 72-kDa gelatinase MMP-2 on fibroblasts and fibrosarcoma cells.
Ingvarsen S; Madsen DH; Hillig T; Lund LR; Holmbeck K; Behrendt N; Engelholm LH
Biol Chem; 2008 Jul; 389(7):943-53. PubMed ID: 18627313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
